LIMPH was founded at Rutgers University - New Brunswick in Fall 2018. Our mission is to build next-generation biosensing technologies for a deeper understanding of immunology, individualized monitoring of infectious diseases, engineering the immune response, and developing point-of-care sensors for global health applications.
佛跳墙破解免登录
Our research group is developing smartphone enabled point-of-care diagnostic sensors and systems. We are quantifying multiple biomarkers associated with diagnostics for many infectious diseases like HIV and Sepsis.
佛跳墙破解免登录
We are working on multiple technologies to perform multiplexing and biomarker detection. This includes monitoring personalized immune response of infected patients including quantifying cells, proteins, exosomes, micrpRNAs, and phagocytes in clinical studies.
佛跳墙破解免登录
Smartphone enabled Point-of-Care Biosensors are being developed to quantify multiple biomolecules in biological samples for disease diagnostic applications. We can enumerate the bioentities from sub-micron to micron ranges in microfluidic devices in clinical studies.
佛跳墙破解免登录
We are developing a sensor to quantify the phagocytic ability of blood cells in infectious diseases. Further, we are coming up with biochemical and non-biochemical strategies to engineer phagocytic ability of blood cells in various immunological conditions.
佛跳墙破解免登录
Manjaro 安装体验小结 - 知乎:Manjaro 简介Manjaro 是一款基于 Arch Linux、对用户友好的 Linux 发行版。在 Linux 社区,Arch Linux 的确是一个异常快速、强大、轻量级的发行版,它提供最新的、最全的软件。然而,Arch Linux 面向高级用 …
佛跳墙破解免登录
We are synthesizing different modalities of eco-friendly silver nanoparticles including beads, rods, nanowires and using them for multiple applications including water purification, air filtration, antimicrobial applications and wound healing.
佛跳墙破解免登录
The core objective of our research group is to achieve global health equity. To achieve this, we build next-generation biosensing technologies for a deeper understanding of immunology, individualized monitoring of infectious diseases, engineering the immune response, and developing point-of-care sensors for global health applications. Our strategy encompasses the comprehensive clinical translation pathway from biosensor development, characterization, and finally its validation in multi-center clinical studies.
挂ssr加速软件
The video tour to the Rutgers The State University of New Jersey. Enjoy!
佛跳墙破解免登录
Manjaro 安装体验小结 - 知乎:Manjaro 简介Manjaro 是一款基于 Arch Linux、对用户友好的 Linux 发行版。在 Linux 社区,Arch Linux 的确是一个异常快速、强大、轻量级的发行版,它提供最新的、最全的软件。然而,Arch Linux 面向高级用 …
May, 2023
LIMPH received Rutgers Global - International Collaborative Research Grant
May, 2023
LIMPH received VCRI Exploratory Seed Grant
October, 2018
VIEW ALL
-->
佛跳墙破解免登录
Core focus areas of our research group are:
挂ssr加速软件 Our mission is to improve health and achieve equity in health in global settings by developing point-of-care technologies. We work on many diseases including HIV/AIDS, Cancer, Sepsis etc.
Next Generation Biosensor Development: We develop next generation biosensors for multiplexed inflammatory biomarker detection in various disease conditions for diagnostics and prognostics.
Manjaro 安装体验小结 - 知乎:Manjaro 简介Manjaro 是一款基于 Arch Linux、对用户友好的 Linux 发行版。在 Linux 社区,Arch Linux 的确是一个异常快速、强大、轻量级的发行版,它提供最新的、最全的软件。然而,Arch Linux 面向高级用 … We develop predictive machine learning systems for personalized patient stratification by employing sensors and clinical data.
挂ssr加速软件 We develop novel methodologies to engineer and modulate the desired immune response using reconfigured therapeutics and novel non-biochemical techniques.
SELECTED PUBLICATIONS
U. Hassan, R. Zhu, and R. Bashir.
Multivariate Computational Analysis of Biosensor's Data for Improved CD64 Quantification for Sepsis Diagnosis, Lab Chip, 18, 1231-1240, (2018)
Publisher's website
U. Hassan, T. Ghonge, B. Reddy Jr., M. Patel, M. Rappleye, et.al.
A point-of-care microfluidic biochip for quantification of CD64 expression from whole blood for sepsis stratification,
Nature Communications, 8, 15949, (2017)
Publisher's website
U. Hassan, N. Watkins, B. Reddy, G. Damhorst, and R. Bashir.